FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities research analysts at Zacks Small Cap lifted their FY2027 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Tuesday, February 3rd. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.74) for the year, up from their prior forecast of ($0.77). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.

Other equities research analysts have also issued research reports about the stock. Noble Financial began coverage on shares of Cardiff Oncology in a research note on Monday, January 5th. They set an “outperform” rating and a $12.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.13.

Cardiff Oncology Price Performance

NASDAQ:CRDF opened at $1.48 on Thursday. The firm’s 50-day moving average price is $2.54 and its 200-day moving average price is $2.41. The company has a market capitalization of $99.69 million, a PE ratio of -1.87 and a beta of 1.33. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.99.

Institutional Trading of Cardiff Oncology

Several institutional investors have recently added to or reduced their stakes in CRDF. The Manufacturers Life Insurance Company raised its stake in shares of Cardiff Oncology by 23.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after purchasing an additional 4,232 shares during the last quarter. SteelPeak Wealth LLC increased its holdings in Cardiff Oncology by 23.2% in the 2nd quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock worth $72,000 after buying an additional 4,300 shares in the last quarter. Invesco Ltd. raised its position in Cardiff Oncology by 24.9% in the 2nd quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after buying an additional 4,749 shares during the last quarter. AlphaCore Capital LLC raised its position in Cardiff Oncology by 8.2% in the 3rd quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock worth $226,000 after buying an additional 8,351 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its stake in Cardiff Oncology by 70.1% during the 3rd quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after acquiring an additional 9,740 shares during the period. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.